Vantia Ltd Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Chilworth United Kingdom (2007)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2008
NCT00879138
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

fedovapagon (10 trials)

Drugs in Phase 2 Trials (1)

va111913 (2 trials)

Drugs in Phase 1 Trials (3)

itraconazole (sporanox) (1 trial)

moxifloxacin (avelox) (1 trial)

rifampin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dysmenorrhea (Phase 2)

Hyperplasia (Phase 3)

Hypertrophy (Phase 1)

Nocturia (Phase 3)

Prostatic Hyperplasia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial APIs: 5